Contact Us

Detecting lung cancer early with advanced flow cytometry


CyPath® Lung is a non-invasive, cost-effective, and accurate test to detect early-stage lung cancer in patients at high risk.


Through our subsidiary, OncoSelect® Therapeutics, we are advancing our discoveries to create broad-spectrum cancer therapeutics.

Early Detection of Cancer and Targeted Treatment Saves Lives

Early Detection of Lung Cancer with Flow Cytometry

bioAffinity Technologies has developed a cost-effective, non-invasive, and accurate test called CyPath® Lung used after lung cancer screening by Low Dose CT  to detect early-stage lung cancer. Physicians can order CyPath® Lung for their patients at high risk for lung cancer.


22211 W Interstate 10
Suite 1206
San Antonio, TX 78257


The Harvey Sandler Cancer Research Laboratories
Science Research Laboratories
Suite 1.424
University of Texas San Antonio
San Antonio, Texas   78249

Contact Info
Main Office: (210) 698-5334
Sales: (210) 426-1086

Investor Relations

Tiberend Strategic Advisors, Inc.
35 W. 35th Street, 11th Floor
New York, NY 10001-0080
T: 212-375-2689

Jonathan Nugent:
David Irish:

Contact Us

Precision Pathology Services

Learn More about CyPath® Lung

The CyPath® Lung Flow Cytometry Test has been licensed by Precision Pathology Services for commercial sale as a Laboratory Developed Test (LDT).

CyPath® Lung is a non-invasive test that assists clinical decision-making in lung cancer patients whose low-dose computed tomography (LDCT) has demonstrated a suspicious finding.

The test reveals the lung micro-environment by automated analysis of sputum using flow cytometry to characterize cell populations indicative of cancer in the lung.

Physician Portal

Patient Portal

How to Order

CyPath® FAQ